REQUEST A DEMO
Total
USD $0.00
Search more companies

Nexus Bioceuticals Sdn. Bhd. (Malaysia)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Nexus Bioceuticals Sdn. Bhd. Profile Updated: August 31, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Nexus Bioceuticals Sdn. Bhd. is an enterprise located in Malaysia, with the main office in Petaling Jaya. It operates in the Medicinal and Botanical Manufacturing sector. It was first established on September 26, 2017. There was a net sales revenue increase of 38.58% reported in Nexus Bioceuticals Sdn. Bhd.’s latest financial highlights for 2022. Its’ total assets recorded a growth of 7.33%. In 2022, Nexus Bioceuticals Sdn. Bhd.’s net profit margin decreased by 6.23%.

Headquarters
Unit C-02-08 (Lobby 4),Block C, Damansara Intan,No.1, Jalan Ss 20/27,
Petaling Jaya; Selangor; Postal Code: 47400

Contact Details: Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.
Financial Auditors:
Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.
Incorporation Date:
September 26, 2017
Key Executives
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Company Performance
Financial values in the chart are available after Nexus Bioceuticals Sdn. Bhd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency MYR. Absolute financial data is included in the purchased report.
Net sales revenue
38.58%
Total operating revenue
38.58%
Operating profit (EBIT)
-65.38%
EBITDA
-46.81%
Net Profit (Loss) for the Period
-63.16%
Total assets
7.33%
Total equity
15.13%
Operating Profit Margin (ROS)
-9.51%
Net Profit Margin
-6.23%
Return on Equity (ROE)
-27.93%
Debt to Equity Ratio
-55.46%
Quick Ratio
0.16%
Cash Ratio
0.23%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?